Simian virus 40 vectors for pulmonary gene therapy
2007

Using SV40 Vectors for Lung Gene Therapy in Sepsis

Sample size: 8 publication 10 minutes Evidence: moderate

Author Information

Author(s): Eid Luminita, Bromberg Zohar, EL-Latif Mahmoud Abd, Zeira Evelyn, Oppenheim Ariella, Weiss Yoram G

Primary Institution: Hadassah – Hebrew University Medical Center

Hypothesis

Can simian virus 40 (SV40) vectors be effectively used for pulmonary gene therapy in sepsis-induced acute respiratory distress syndrome (ARDS)?

Conclusion

The study demonstrated that SV40 vectors can efficiently transduce and express genes in the lungs of rats with sepsis-induced ARDS.

Supporting Evidence

  • SV40 vectors were shown to be nonimmunogenic, allowing repeated administrations.
  • Luciferase expression was significantly higher in septic rats treated with SV40 vectors compared to controls.
  • The vector efficiently transduced alveolar type II cells, which are important for lung repair.

Takeaway

Researchers found a way to use a virus to deliver genes to the lungs of sick rats, which could help treat lung problems caused by infections.

Methodology

The study involved inducing sepsis in rats and administering SV40 vectors intratracheally, followed by evaluation of gene expression through light detection and immunostaining.

Potential Biases

There may be a risk of bias due to the small sample size and the specific animal model used.

Limitations

The study was limited to a 48-hour observation period, and the expression of the reporter gene was moderate.

Participant Demographics

Sprague-Dawley rats were used in the study.

Statistical Information

P-Value

p<0.03

Statistical Significance

p<0.03

Digital Object Identifier (DOI)

10.1186/1465-9921-8-74

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication